Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Q32 BioQTTB | Open-market buy | 05/28 | 06/01 | 1,875,000 sh2 trades | $8.00avg. | $15,000,000 | No record | |
Q32 BioQTTB | Open-market buy | 05/28 | 06/01 | 1,875,000 sh2 trades | $8.00avg. | $15,000,000 | No record | |
Q32 BioQTTB | Open-market buy | 05/28 | 06/01 | 1,875,000 sh2 trades | $8.00avg. | $15,000,000 | No record | |
Q32 BioQTTB | Open-market buy | 05/28 | 06/01 | 1,875,000 sh2 trades | $8.00avg. | $15,000,000 | No record | |
Q32 BioQTTB | Open-market sale | 02/25 | 02/27 | 9,896 sh | $4.51 | $44,630.96 | −10.0% | |
Lee KalowskiCFO and President | Q32 BioQTTB | Open-market sale | 02/25 | 02/27 | 3,995 sh | $4.51 | $18,017.45 | −10.0% |
Shelia M. VioletteChief Scientific Officer | Q32 BioQTTB | Open-market sale | 02/25 | 02/27 | 2,815 sh | $4.51 | $12,695.65 | −4.8% |
Q32 BioQTTB | Open-market sale | 25/12/02 | 25/12/04 | 22,506 sh | $3.46 | $77,870.76 | −18.5% | |
Lee KalowskiCFO and President | Q32 BioQTTB | Open-market sale | 25/12/02 | 25/12/04 | 9,072 sh | $3.46 | $31,389.12 | −18.5% |
Q32 BioQTTB | Open-market sale | 25/08/26 | 25/08/28 | 10,494 sh | $1.80 | $18,889.2 | −8.0% | |
Lee KalowskiCFO and President | Q32 BioQTTB | Open-market sale | 25/08/26 | 25/08/28 | 4,240 sh | $1.80 | $7,632 | −8.0% |
Shelia M. VioletteChief Scientific Officer | Q32 BioQTTB | Open-market sale | 25/08/26 | 25/08/28 | 2,990 sh | $1.80 | $5,382 | −4.9% |
Arthur TzianabosDirector | Q32 BioQTTB | Open-market sale | 24/03/25 | 24/08/14 | 265 sh | $24.20 | $6,413 | −3.2% |
Paul AllowaySEE REMARKS | Q32 BioQTTB | Open-market sale | 24/03/25 | 24/04/23 | 268 sh | $24.21 | $6,488.28 | −9.4% |
Charles Michaud Jr.SEE REMARKS | Q32 BioQTTB | Open-market sale | 24/03/25 | 24/04/23 | 75 sh | $24.20 | $1,815 | −7.5% |